RIGL Dec 2024 1.000 call
- PR Newswire
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced one oral and four poster presentations at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain being held June 13-16, 2024, and online. The oral presentation includes five-year results from the pivotal cohort of the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) for the treatment of relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML).
- Simply Wall St.
Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders have endured a 76% loss from investing in the stock three years ago
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the...
- PR Newswire
Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the presentation of three posters at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL today and online. Presentations include five-year results from the pivotal cohort of the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) for the treatment of relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML), the safety and efficacy of olutasidenib treatment
